The study investigates the role of mitochondrial nicotinamide nucleotide transhydrogenase (NNT) in the development of heart failure with preserved ejection fraction (HFpEF), particularly in the context of cardiometabolic disease. HFpEF is a complex condition lacking effective therapies, and current preclinical models often rely on a “two-hit” approach—combining a high-fat diet with L-NAME (a nitric oxide synthase inhibitor)—to induce HFpEF-like features in mice.
The article explores the current understanding, challenges, and recommendations for the use of transcatheter therapies in treating mitral regurgitation (MR) and tricuspid regurgitation (TR) in patients with heart failure (HF). MR and TR are the most prevalent valvular heart diseases in heart failure patients, especially among those with reduced ejection fraction or advanced HF. Their independent prognostic importance is well established. In recent years, transcatheter interventions have emerged as potential treatment options.
The study explored the link between calprotectin—a protein released during inflammation—and the risk of developing atherosclerotic cardiovascular disease (ASCVD), which includes conditions like heart attacks and strokes. Researchers followed over 2400 people from a racially diverse population in Dallas for eight years, measuring calprotectin levels in their blood and observing who later experienced heart-related events.
This research focuses on a serious condition during pregnancy called pre-eclampsia, which affects about 5% of pregnant women. It usually shows up after the 20th week and is marked by high blood pressure and protein in the urine. If not managed, it can lead to dangerous complications for both the mother and the baby, including seizures, liver and kidney issues, and even death.
Recent prescription trends for novel heart failure medications were analyzed at a major Kansas City safety net hospital, focusing on the utilization patterns of sacubitril/valsartan and SGLT2 inhibitors in underserved populations. The study examined prescription data from October 2021 to October 2022, involving 769 patients receiving sacubitril/valsartan and 2,287 patients prescribed SGLT2 inhibitors.
Heart failure (HF) is a growing problem worldwide, causing high healthcare costs and lower quality of life. While medications are key, lifestyle changes like diet, exercise, and managing weight, smoking, and stress are also important. These changes, along with medicines, can improve how well patients do, reduce hospital visits, and help the medicines work better.
